A clinical trial to determine action mechanism of blinatumomab and to explore dynamics changes of immune microenvironment in pediatric B-ALL in single cell level in Pediatric B-ALL patients with high-risk or MRD≥1%
Latest Information Update: 18 Sep 2024
At a glance
- Drugs Blinatumomab (Primary)
- Indications Precursor B-cell lymphoblastic leukaemia-lymphoma
- Focus Pharmacodynamics
- 18 Sep 2024 New trial record
- 16 Sep 2024 According to presented at the 29th Congress of the European Haematology Association, this study is ongoing with larger sample size.